List of Wound Healing Companies in Texas - 8

Crown Aesthetics, the premier medical aesthetics company, is dedicated to helping leading plastic surgeons, dermatologists, and aesthetic physicians around the world grow their businesses. We do that by delivering dramatic results in rejuvenation and restoration. Our non-invasive innovations – SkinPen®, the first FDA-cleared microneedling device; the post-microneedling protocol Skinfuse® and the platelet-rich plasma system ProGen™ – act as "gateway" products that draw new consumers to practices. Based in Dallas, Texas, Crown Aesthetics sets industry standards for efficacy, safety, and innovation. As a result, our customers consistently deliver the best aesthetic care in the business. Learn more at CrownAesthetics.com.

Direct Biologics is a market-leading innovator in regenerative medicine.

FibroBiologics is the world leader in cell therapy using fibroblasts to regenerate tissue and cure chronic diseases. Currently, FibroBiologics holds 150+ U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, and Cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.

Progenitec is a healthcare company that facilitates faster healing of chronic wounds through accurate and fast diagnosis.

With our focus on improving patient outcomes with evidence-based healing solutions, Sanara MedTech Inc. develops, markets and distributes surgical, wound care and skin care products to physicians, hospitals, clinics and all post-acute care settings. We are constantly seeking long-term strategic partnerships with a focus on products that produce efficacious outcomes at a lower overall cost. Our primary products are sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech sells and distributes CellerateRX® Surgical Activated Collagen® Powder to the surgical market and BIAKŌS™ Antimicrobial Skin and Wound Cleanser, Irrigation Solution, and Wound Gel, HYCOL® Hydrolyzed Collagen, and PULSAR II™ Advanced Wound Irrigation System (AWI™) to the wound care market.

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by "Seeing the Unknown®" with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of changing the current standard of care in the future, DeepView® is expected to provide faster and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs.

Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will enable physicians to better manage a variety of indications involving inflammation and the body's response to injury. aCT1 is a patented new chemical entity currently in development for multiple indications. The Company's lead clinical programs include Granexin® gel in dermatology and iNexinTM ophthalmic solution in ophthalmology. The Company also has ongoing preclinical research in pulmonology.

ZZ Biotech is a clinical stage company developing innovative biologic treatments for ischemic stroke, neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. ZZ Biotech was incepted in 2006 to focus on the development of 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. ZZ Biotech’s experimental drug 3K3A-APC is a genetically engineered variant of human activated protein C (APC), a serine protease optimized for human therapeutic use. ZZ Biotech completed RHAPSODY, a placebo-controlled multicenter Phase 2 clinical trial of 3K3A-APC in patients suffering from acute ischemic stroke. The study was supported and funded by the NIH’s National Institute of Neurological Disorder and Stroke (NINDS) through a pair of NeuroNEXT grants. The Phase 2 study evaluated safety, tolerability and vasculoprotective activity of 3K3A-APC when given after tissue plasminogen activator (tPA), mechanical thrombectomy, or both, in patients who have experienced moderate to severe ischemic stroke. 3K3A-APC was deemed safe and well-tolerated at all dose levels tested. Furthermore, intracerebral bleeding was substantially reduced in patients treated with 3K3A-APC. In June 2020 the FDA designated the investigation of the ZZ Biotech’s experimental drug 3K3A-APC for the treatment of acute ischemic stroke as a Fast Track development program. In May of 2022 the NINDS awarded $4 million of a grant budgeted to total approximately $30 million to researchers at the Keck School of Medicine of USC to conduct a pivotal Phase 3 clinical trial in acute ischemic stroke using 3K3A-APC. The multinational trial, to be run in the NIH StrokeNet, will commence in 2023. ZZ Biotech also has active clinical programs in ALS and wound healing. 3K3A-APC’s unique multi-modal mechanism of action is well suited to address both of these areas of great unmet medical need.